- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
London School of Economics Establishes Market Access Academy
January 24, 2017
â¨The London School of Economics and Political Science (LSE) and Boston Consulting Group (BCG) have partnered with leading big pharma companies to create The LSE Health Market Access Academy, which aims "to train top performers from all of the world’s leading pharma companies, giving them advanced knowledge and strategies in the field of market access".
AbbVie, AstraZeneca, Amgen, Bayer, Eli Lilly, Janssen, Merck EMD, Pfizer, Roche, Sanofi, Takeda and UCB have joined the initiative to create "what will be the first collaborative market access management development program".
The weeklong program will consist of five modules that aim to deepen participants’ market access knowledge, exploring areas such as understanding access drivers and barriers, defining an integrated evidence package, creating a receptive access environment, optimizing access and value, and managing access strategy.
The first two waves of the LSE Health Market Access Academy will take place March 27-31 and September 11-15, 2017 in London, with future international delivery dates to be announced in 2018.
LSE Health encourages applications through their website, www.LSEMarketAccess.com.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
